Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will participate in a panel focused on hereditary angioedema (HAE) at the 2024 Wedbush PacGrow Healthcare Conference on August 14 in New York, NY.

Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a panel titled, “HAE Ya! The Changing Face of the HAE Therapeutic Landscape” on Wednesday, August 14 at 2:30pm ET.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  218.76
-3.27 (-1.47%)
AAPL  260.08
-2.69 (-1.02%)
AMD  239.16
+1.13 (0.48%)
BAC  51.09
-0.44 (-0.84%)
GOOG  255.58
+4.24 (1.69%)
META  739.65
+6.38 (0.87%)
MSFT  523.29
+5.63 (1.09%)
NVDA  182.86
+1.70 (0.94%)
ORCL  275.36
+0.21 (0.08%)
TSLA  441.15
-1.45 (-0.33%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.